Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis.
Adjuvant radiation therapy
Boost
Breast-conservation therapy
Early breast cancer
Intraoperative radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
10
01
2021
accepted:
07
04
2021
pubmed:
4
5
2021
medline:
1
4
2022
entrez:
3
5
2021
Statut:
ppublish
Résumé
There are currently no data from randomized controlled trials on the use of intraoperative radiotherapy (IORT) as a tumor bed boost as part of a breast-conservation approach for breast cancer. This study retrospectively reviewed the safety and efficacy of IORT as a boost treatment at a tertiary cancer center. From 2015 to 2019, patients underwent breast-conserving surgery with axillary lymph node staging and a single dose of 20 Gy IORT with 50-kV photons, followed by whole-breast irradiation (WBI) and adjuvant systemic therapy (if applicable). Patients were followed for assessment of acute and late toxicities (using the Common Terminology Criteria for Adverse Events version 5.0) at 3-6-month intervals. Outcomes included ipsilateral (IBTR) and contralateral breast progression-free survival (CBE), distant metastasis-free survival (DMFS), and overall survival (OS). Median follow-up for the 214 patients was 28 (range 2-59) months. Most patients had T1 disease (n = 124) and were clinically node negative. Only few patients had high-grade and/or triple-negative disease. The vast majority of patients underwent sentinel node biopsy, and 32 (15%) required re-resection for initially positive margins. Finally, all tumor bed margins were clear. Nine (4.2%) and 48 (22.4%) patients underwent neoadjuvant and adjuvant chemotherapy, respectively. WBI was predominantly performed as conventionally fractionated WBI (n = 187, 87.4%), and the median time from BCS to WBI was 54.5 days. IORT was delivered with a single dose of 20 Gy. The median WBI dose was 50 Gy (range 29.4-50.4 Gy). No patients experienced grade 4 events; acute grade 3 toxicities were limited to 17 (8%) cases of radiation dermatitis. Postoperative toxicities were mild. After WBI only one case of late grade ≥ 2 events was reported. There were two recurrences in the tumor bed and one contralateral breast event. This investigation provides additional preliminary data supporting the using of IORT in the boost setting and corroborates the existing literature. These encouraging results should be prospectively validated by the eventual publication of randomized studies such as TARGIT‑B.
Sections du résumé
BACKGROUND
There are currently no data from randomized controlled trials on the use of intraoperative radiotherapy (IORT) as a tumor bed boost as part of a breast-conservation approach for breast cancer. This study retrospectively reviewed the safety and efficacy of IORT as a boost treatment at a tertiary cancer center.
METHODS
From 2015 to 2019, patients underwent breast-conserving surgery with axillary lymph node staging and a single dose of 20 Gy IORT with 50-kV photons, followed by whole-breast irradiation (WBI) and adjuvant systemic therapy (if applicable). Patients were followed for assessment of acute and late toxicities (using the Common Terminology Criteria for Adverse Events version 5.0) at 3-6-month intervals. Outcomes included ipsilateral (IBTR) and contralateral breast progression-free survival (CBE), distant metastasis-free survival (DMFS), and overall survival (OS).
RESULTS
Median follow-up for the 214 patients was 28 (range 2-59) months. Most patients had T1 disease (n = 124) and were clinically node negative. Only few patients had high-grade and/or triple-negative disease. The vast majority of patients underwent sentinel node biopsy, and 32 (15%) required re-resection for initially positive margins. Finally, all tumor bed margins were clear. Nine (4.2%) and 48 (22.4%) patients underwent neoadjuvant and adjuvant chemotherapy, respectively. WBI was predominantly performed as conventionally fractionated WBI (n = 187, 87.4%), and the median time from BCS to WBI was 54.5 days. IORT was delivered with a single dose of 20 Gy. The median WBI dose was 50 Gy (range 29.4-50.4 Gy). No patients experienced grade 4 events; acute grade 3 toxicities were limited to 17 (8%) cases of radiation dermatitis. Postoperative toxicities were mild. After WBI only one case of late grade ≥ 2 events was reported. There were two recurrences in the tumor bed and one contralateral breast event.
CONCLUSION
This investigation provides additional preliminary data supporting the using of IORT in the boost setting and corroborates the existing literature. These encouraging results should be prospectively validated by the eventual publication of randomized studies such as TARGIT‑B.
Identifiants
pubmed: 33938966
doi: 10.1007/s00066-021-01785-2
pii: 10.1007/s00066-021-01785-2
pmc: PMC8397646
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
812-819Informations de copyright
© 2021. The Author(s).
Références
Radiother Oncol. 2021 Jan;154:179-186
pubmed: 32980384
Ann Surg Oncol. 2021 May;28(5):2512-2521
pubmed: 33433786
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Breast Care (Basel). 2018 Jul;13(3):162-167
pubmed: 30069175
Front Oncol. 2017 Dec 22;7:317
pubmed: 29312887
Radiother Oncol. 2013 Aug;108(2):279-86
pubmed: 23830467
Radiother Oncol. 1987 Aug;9(4):299-310
pubmed: 3317524
Lancet Oncol. 2008 Apr;9(4):331-41
pubmed: 18356109
Lancet Oncol. 2013 Dec;14(13):1269-77
pubmed: 24225155
Ann Surg Oncol. 2010 Oct;17 Suppl 3:352-8
pubmed: 20853058
Lancet Oncol. 2010 Mar;11(3):231-40
pubmed: 20138809
Breast. 2008 Dec;17(6):617-22
pubmed: 18650091
Radiat Oncol. 2020 Oct 13;15(1):235
pubmed: 33050920
Strahlenther Onkol. 2016 Jan;192(1):1-7
pubmed: 26403912
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1309-14
pubmed: 20100643
Ann Surg Oncol. 2010 May;17(5):1375-91
pubmed: 20140531
Int J Breast Cancer. 2014;2014:472516
pubmed: 25258684
J Clin Oncol. 2020 Oct 1;38(28):3261-3272
pubmed: 32663119
Ecancermedicalscience. 2017 Jun 29;11:750
pubmed: 28717396
Lancet Oncol. 2006 Jun;7(6):467-71
pubmed: 16750496
Clin Cancer Res. 2008 Mar 1;14(5):1325-32
pubmed: 18316551
Clin Oncol (R Coll Radiol). 2021 Jan;33(1):30-39
pubmed: 32711920
Strahlenther Onkol. 2020 Apr;196(4):349-355
pubmed: 31641788
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):485-93
pubmed: 18407434
Radiother Oncol. 2010 Dec;97(3):530-4
pubmed: 20934763
Lancet. 2008 Mar 29;371(9618):1098-107
pubmed: 18355913
Radiother Oncol. 2020 May;146:136-142
pubmed: 32151790
Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):73-9
pubmed: 24331652
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):267-274
pubmed: 31175905
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1091-7
pubmed: 20951505
Semin Radiat Oncol. 2008 Oct;18(4):257-64
pubmed: 18725113
Int J Radiat Oncol Biol Phys. 1985 Jan;11(1):87-96
pubmed: 3881377
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1410-5
pubmed: 16442241
Radiother Oncol. 2015 Jun;115(3):342-8
pubmed: 26104975
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Lancet. 2014 Feb 15;383(9917):603-13
pubmed: 24224997
Oncogene. 2016 Sep 15;35(37):4914-26
pubmed: 26876200
BMJ Open. 2016 May 09;6(5):e010703
pubmed: 27160842
J Natl Cancer Inst. 2002 Aug 7;94(15):1143-50
pubmed: 12165639
Int J Cancer. 2015 Mar 1;136(5):1193-201
pubmed: 24995409
Breast J. 2014 Mar-Apr;20(2):125-30
pubmed: 24372873
Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):209-13
pubmed: 16111591
Lancet Oncol. 2015 Jan;16(1):47-56
pubmed: 25500422